Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Although many patients with venous thromboembolism require extended treatment, it is uncertain whether it is better to use full- or lower-intensity anticoagulation therapy or aspirin. METHODS: In this randomized, double-blind, phase 3 study, we assigned 3396 patients with venous thromboembolism to receive either once-daily rivaroxaban (at doses of 20 mg or 10 mg) or 100 mg of aspirin. All the study patients had completed 6 to 12 months of anticoagulation therapy and were in equipoise regarding the need for continued anticoagulation. Study drugs were administered for up to 12 months. The primary efficacy outcome was symptomatic recurrent fatal or nonfatal venous thromboembolism, and the principal safety outcome was major bleeding. RESULTS: A total of 3365 patients were included in the intention-to-treat analyses (median treatment duration, 351 days). The primary efficacy outcome occurred in 17 of 1107 patients (1.5%) receiving 20 mg of rivaroxaban and in 13 of 1127 patients (1.2%) receiving 10 mg of rivaroxaban, as compared with 50 of 1131 patients (4.4%) receiving aspirin (hazard ratio for 20 mg of rivaroxaban vs. aspirin, 0.34; 95% confidence interval [CI], 0.20 to 0.59; hazard ratio for 10 mg of rivaroxaban vs. aspirin, 0.26; 95% CI, 0.14 to 0.47; P<0.001 for both comparisons). Rates of major bleeding were 0.5% in the group receiving 20 mg of rivaroxaban, 0.4% in the group receiving 10 mg of rivaroxaban, and 0.3% in the aspirin group; the rates of clinically relevant nonmajor bleeding were 2.7%, 2.0%, and 1.8%, respectively. The incidence of adverse events was similar in all three groups. CONCLUSIONS: Among patients with venous thromboembolism in equipoise for continued anticoagulation, the risk of a recurrent event was significantly lower with rivaroxaban at either a treatment dose (20 mg) or a prophylactic dose (10 mg) than with aspirin, without a significant increase in bleeding rates. (Funded by Bayer Pharmaceuticals; EINSTEIN CHOICE ClinicalTrials.gov number, NCT02064439 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Consequently, several studies have investigated the role of aspirin for the secondary prevention of VTE. 309,314,315”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [314]
The cited source says what the claim attributes to it.
In the citing paper
“Two of these agents, rivaroxaban and apixaban, have been studied at a reduced dose: from 20 mg daily to 10 mg daily for rivaroxaban and 5 mg to 2.5 mg twice daily for apixaban. 306,314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [314]
The cited source says what the claim attributes to it.
In the citing paper
“Three DOACs have been studied for secondary prevention of recurrent VTE after completion of the primary treatment phase. 306,310,314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [314]
The cited source says what the claim attributes to it.
In the citing paper
“We identified 2 RCTs 306,314 to inform this recommendation.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [314]
The cited source says what the claim attributes to it.
In the citing paper
“and a single study comparing 2 doses of the direct oral anticoagulant rivaroxaban and aspirin found that anticoagulation was more effective than aspirin without an increase in bleeding rates. 314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [314]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Self-citationSCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
Antithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
Self-citationSCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Büller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302507 · Cited by 2,324
Self-citationThe Statistical Analysis of Failure Time Data
Klein, J. P. (1982) · Technometrics · doi:10.1080/00401706.1982.10487769 · Cited by 2,215
Research works printed but not linked: 1
- 2012, MMWR Morb Mortal Wkly Rep, 61, 401
Cited by
Items 701–786 of 786
Yamada, N., Fu, W., Shi, Z., Park, K. H., Kim, H.-S., Dai, X., Lensing, A. W. A., Pap, A. F., Kohno, T., Tajima, T., et al. (2024) · Thrombosis Journal · doi:10.1186/s12959-024-00609-4
Self-citationBasics of Management of Acute Pulmonary Embolism for the Acute Physician
Boutrus, T. S. (2024) · Journal of Internal Medicine and Emergency Research · doi:10.37191/mapsci-2582-7367-5(2)-074
Rivaroxaban’s vascular dose for the neurovascular clinician
Chong, J. Y., & Jan, K. (2024) · Chinese Neurosurgical Journal · doi:10.1186/s41016-024-00373-4
Lungenembolie: ambulante Therapie und Nachsorge
Hobohm, L., & Keller, K. (2024) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2252-7665
Cusick, A. (2025) · doi:10.1093/med/9780197754153.003.0074
Mitchell, L. G., & Rodriguez, V. (2025) · The Lancet Haematology · doi:10.1016/s2352-3026(25)00109-7
Groat, D., Martin, K. A., Rosovsky, R. P. G., Sanfilippo, K. M., Gaddh, M., Kreuziger, L. B., Federici, E. H., & Woller, S. C. (2025) · Thrombosis Research · doi:10.1016/j.thromres.2025.109338
Bell, C., & Carlin, S. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-01856-jc
Menstrual bleeding-specific quality of life in women on antiplatelet therapy
Kempers, E. K., van der Zande, J. A., Janssen, P. M., Cornette, J. M. J., Roos‐Hesselink, J. W., & Kruip, M. J. H. A. (2025) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2025.102910
Terapias anticoagulantes 86 años después. Viejas y nuevas drogas. Viejos y nuevos errores
Korin, D. (2025) · Revista Hematología · doi:10.48057/hematologa.v29i1.627
Monagle, P., & Bannow, B. S. (2022) · doi:10.1182/ashsap8.chapter09
Introduction to venous thromboembolism and antithrombotic drugs
Shatzel, J. J. (2025) · doi:10.1182/ashsap9.chapter15
Umetsu, M., Yamaki, T., Ogawa, T., Nishibe, T., Shiraishi, Y., Yamada, N., Matsumoto, T., Nomura, T., Tabuchi, A., Yamashita, Y., et al. (2025) · Annals of Vascular Diseases · doi:10.3400/avd.oa.25-00061
When viral myocarditis meets thrombosis tendency: deep analysis of a complex case report
Ding, Q., Zhang, Y., Li, D., Liu, W., Feng, J., Li, S., Chen, W., & Guo, M. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1641074
Pastori, D., Menichelli, D., Podda, G. M., Clerici, B., Birocchi, S., Bucci, T., Ames, P. R. J., & Pignatelli, P. (2025) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-025-03158-3
Koitabashi, Y., Ghazali, N., Sheshadri, A., & Farooqi, B. (2025) · Journal of Clinical Question · doi:10.69854/jcq.2025.0020
Fominykh, Y. A., Робертович, Б. Э., Galagudza, M. M., & Майорова, А. М. (2025) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-234-2-163-171
From Algorithms to Biomarkers: Toward Personalized Management of Venous Thromboembolism
Boccatonda, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14176172
Crichi, B., Delrue, M., & Frère, C. (2025) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2025.103170
Deshpande, P., Ganguly, K., Yadav, G., & Jain, S. (2025) · Indian Journal of Arthroplasty · doi:10.5005/ijoa-11025-0024
Platelets in Venous Thromboembolism
Riedl, J. (2025) · Springer eBooks · doi:10.1007/978-3-031-96352-0_13
Mohith, K., Rajesh, S., Gopi, A., Modi, M. A., Gupta, A. K., Shahi, S., Dodhia, A. R., Fahad, N. Y., Gautam, S., Chhabra, P., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-8066325/v1
Liuzzo, G., & Patrono, C. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf967
Венозная тромбоэмболия. Что нас ждет впереди?
Васильевна, С. О., & Львовна, Е. А. (2025) · Malignant tumours · doi:10.18027/2224-5057-2025-15-3s1-60-65
Acute Venous Thromboembolism: A Historical Perspective
Tapson, V. F. (2025) · Springer eBooks · doi:10.1007/978-3-030-70904-4_1-1
Liu, Z.-Y., Zhang, H.-X., Ma, L., Mu, G.-Y., Xie, Q.-F., Zhou, S., Wang, Z.-N., Wang, Z., Hu, K., Xiang, Q., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19359837
Ma, S., Fan, G., Xu, F., Zhang, X., Chen, Y., Tao, Y., Li, Y., Lyu, Y., Yang, P., Wang, D., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26677073
Hu, B., Jiang, L., Tang, H., Hu, M., Yu, J., & 戴泽平 (2021) · Figshare · doi:10.6084/m9.figshare.14006197
Liu, Z.-Y., Zhang, H.-X., Ma, L., Mu, G.-Y., Xie, Q.-F., Zhou, S., Wang, Z.-N., Wang, Z., Hu, K., Xiang, Q., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19359834
Li, J., Ma, S., Jia, X. J., Bu, Y., Zhou, T., Zhang, L., Qiu, M., & Wang, X. (2023) · Figshare · doi:10.6084/m9.figshare.23542921
Chen, X., Huang, W., Sun, A., Wang, L., Mo, F., & Guo, W. (2021) · Figshare · doi:10.6084/m9.figshare.16726954
Liu, Z.-Y., Zhang, H.-X., Ma, L., Mu, G.-Y., Xie, Q.-F., Zhou, S., Wang, Z.-N., Wang, Z., Hu, K., Xiang, Q., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19359840
Verlängerte medikamentöse Sekundärprophylaxe venöser Thromboembolien
Bauersachs, R. (2025) · Springer Reference Medizin · doi:10.1007/978-3-662-60880-7_130
Self-citationAntiplatelet Therapy for Venous Thromboembolism
Poénou, G., & Heestermans, M. (2025) · Springer eBooks · doi:10.1007/978-3-031-96360-5_13
Gonzaga, Y. B. D. M., & de Alencar, J. N. (2025) · Seminars in Thrombosis and Hemostasis · doi:10.1055/a-2768-2432
Cheung, C. K. M., Carlin, S., Scheier, T., Yi, Q., Chan, N., Bhagirath, V. C., Petropoulos, J., Wong, R. S. M., Weitz, J. I., & Eikelboom, J. W. (2026) · TH Open · doi:10.1055/a-2798-0066
Self-citationScott, M. (2026) · The Hematologist · doi:10.1182/hem.v23.1.202618
Prescribing patterns of apixaban and rivaroxaban for extended-phase anticoagulant therapy
Patel, M., Mei, C., Shapiro, N. L., & Uppuluri, E. M. (2026) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxag026
Bacha, Z. A. R. Y. A. B., Qazi, K., Khalid, A. A., Shah, Z. A., Khan, M. I., Sikandar, M., Sajjad, F., Saeed, S., Akbar, F., Siddique, K., et al. (2026) · Critical Pathways in Cardiology A Journal of Evidence-Based Medicine · doi:10.1097/hpc.0000000000000417
Palareti, G. (2026) · Springer eBooks · doi:10.1007/978-3-031-82232-2_67
Kamel, K. S. (2026) · Internal Medicine Journal · doi:10.1111/imj.70353
Gillis, S., Phelan, E., Pitman, J., Trenaman, S. C., Battistella, M., Sanyal, C., Daley, C. J. A., Tennankore, K., Gillis, L., & Wilson, J. A. (2026) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-026-02096-1
INDICACIONES Y TIPOS DE FILTROS DE VENA CAVA: REVISIÓN SISTEMÁTICA.
Muñoz, L. E., Jaramillo, I. A. H., Tolosa, A. V., Bazán, M. I. O., Sánchez, A. M. M., & Sobradiel, M. G. (2026) · Revista sanitaria de investigación. · doi:10.34896/rsi.2026.88.63.001
Lauw, M. N., Middeldorp, S., & Carrier, M. (2026) · HemaSphere · doi:10.1002/hem3.70327
Kolluri, R., Froehlich, J. B., Abumoawad, A., Merli, G. J., & Topoulos, A. P. (2026) · Vascular Medicine · doi:10.1177/1358863x261426933
Développement clinique de l'EP217609 et de son antidote l'avidine
Guéret, P. (2017) · theses.fr (ABES) · doi:10.70675/03763fe0z9337z4967za3a5z76b9f006fe2e
Joshi, D. K., Kirmani, N., Coy, Z., Agrawal, S. P., Majeed, M. W., Dagostin, C. S., Jain, H., Mansuri, Z. H., Soukas, P. A., Abbott, J. D., et al. (2026) · Journal of the Society for Cardiovascular Angiography & Interventions · doi:10.1016/j.jscai.2026.105317
Post-discharge Pulmonary Embolism Clinic
Troha, D. R., Zahid, I., Rosovsky, R. P., & HOOKS, B. J. (2026) · Springer eBooks · doi:10.1007/978-3-030-70904-4_36-1
Left Atrial Appendage Closure Lacks Sufficient Evidence for Routine Use
Ruzieh, M., Foy, A., & Mandrola, J. M. (2026) · Thrombosis and Haemostasis · doi:10.1055/a-2862-6722
Thrombophilia testing in venous thromboembolism: When, who and why it matters. A practical review
Cordeanu, E., Mirea, C., Zamperini, C., Brouder, S., & Stéphan, D. (2026) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2026.04.004
Mantoo, M. R., Mantoo, D. S. R., Majeed, M. W., Kulkarni, A., Lone, H. P., Mansoor, M., & Roy, A. (2026) · Romanian Journal of Cardiology · doi:10.2478/rjc-2026-0014
Zuin, M., Ageno, W., Squizzato, A., Temporelli, P. L., Bilato, C., & Piazza, G. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04410-1
Steiner, D., Kitta, A., & Ay, C. (2026) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2026.05.030
Emerging strategies in venous thromboembolism: a narrative review of pharmacological innovations
Ye, J., & Huang, K. (2026) · Thrombosis Journal · doi:10.1186/s12959-026-00882-5
The Interplay of Heart Failure and Pulmonary Embolism
Osuna, M. F.-Z., Méndez-Bailón, M., & Rodríguez, P. D. (2026) · Heart Failure Clinics · doi:10.1016/j.hfc.2026.02.006
Vemula, S. S. M., Shah, N., Atti, L., Akanbi, M. O., & Hrinczenko, B. W. (2026) · Cureus · doi:10.7759/cureus.111121
Kounoudi, C., Serraou, E.-A., Stathopoulou, M. S., Hunt, B. J., & Kakkos, S. K. (2026) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2026.06.036
Ceccato, D., Turatti, G., Boscaro, F., Poretto, A., Curri, F., Avruscio, G., & Prandoni, P. (2026) · Research Square · doi:10.21203/rs.3.rs-9994927/v1
Self-citationBleeding Events During Anticoagulation After Acute Pulmonary Embolism: Real-Life Experience
Pocienė, I., Lebednykienė, B., Račkauskienė, J., Averjanovaitė, V., & Danila, E. (2026) · Medicina · doi:10.3390/medicina62071278
Embolia pulmonar: qué aporta la nueva guía AHA/ACC 2026
Briceño, W., & Jiménez, D. (2026) · Revista Clínica Española · doi:10.1016/j.rce.2026.502610
Deleenheer, B., Carlin, S., Chan, N., Coppens, M., Corcos, O., Cuerda, C., Douketis, J. D., Jeppesen, P. B., Joly, F., Lal, S., et al. (2026) · Clinical Nutrition · doi:10.1016/j.clnu.2026.106741
González-Sagredo, A., Salomó, J. H., Villoria, J., Sobrino, T. L., & Videla, S. (2026) · Angiología · doi:10.20960/angiologia.00900
How to Safely Anticoagulate Patients With Renal Impairment
Aziz, N. Z., Haysom, R., Thachil, J. V., & Swan, D. (2026) · British Journal of Hospital Medicine · doi:10.31083/bjhm49737
Biglietto, M., Sorella, S., Baldacci, E., Breccia, M., Chiaretti, S., Capriata, M., Donzelli, L., D’Elia, G. M., Morano, S. G., Giudice, I. D., et al. (2026) · European Journal Of Haematology · doi:10.1111/ejh.70262
Pulmonary embolism: what does the new AHA/ACC 2026 guide add
Briceño, W., & Jiménez, D. (2026) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2026.502610
Kaneda, K., Yamashita, Y., Horie, T., & Ono, K. (2026) · Research Square · doi:10.21203/rs.3.rs-10561239/v1
Yami, M. S. A. (2026) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296261452847
The first month after direct oral anticoagulants: a window of vulnerability
Afzal, A. (2026) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2026.106923
Lorenzo, A., Siniscalchi, C., Morales, S. N., Sancho, T., Valle, R., Gil‐Díaz, A., Sadeghipour, P., Sigüenza, P., Monréal, M., & the RIETE investigators (2026) · Bleeding Thrombosis and Vascular Biology · doi:10.4081/btvb.2026.403
Antiplatelet therapy in pulmonary embolism: Mechanisms and evidence
Kalamara, T.-V., Dodos, K., & Georgakopoulou, V. (2026) · World Journal of Translational Medicine · doi:10.5528/wjtm.121879
The complexity of provoked venous thromboembolism: one treatment plan does not fit all
Peseski, A. M., Kapoor, S., & Ortel, T. L. (2026) · Blood Advances · doi:10.1182/bloodadvances.2025018610
Acute Pulmonary Embolism: Current Concepts in Risk Stratification and Management
Arora, A., Gupta, Y., Jose, R., & Aggarwal, R. (2026) · Indian Journal of Medical Specialities · doi:10.4103/injms.injms_255_26
Espinola–Klein, C., Heiß, C., Brodmann, M., Gary, T., Mazzolai, L., Bura-Rivière, A., Linnemann, B., Aboyans, V., Rodríguez-Palomares, J. F., Klok, F. A., et al. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag481
Marchiano, J. S., & King, O. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44037-3.00063-4
Managing thrombotic risk in myeloproliferative disorders
Gurumurthy, G., Ho, M., Thachil, J. V., & Sriskandarajah, P. (2026) · Expert Review of Hematology · doi:10.1080/17474086.2026.2732981
Drug Selection for Long-Term Anticoagulant Therapy in Patients with Venous Thromboembolism
Rylnikov, D. V., Loginovskaya, E. V., An, E. S., Seliverstov, E. I., & Zolotukhin, I. A. (2026) · Journal of Venous Disorders · doi:10.17116/flebo202620031258
Krebs, J. R., Wakefield, T., & Jacobs, B. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-28432-8.00048-x
Contemporary anticoagulation management in pulmonary embolism
Hammerschlag, G., Yo, S., Lawton, E., & Dunn, A. (2026) · Thrombosis Research · doi:10.1016/j.thromres.2026.109854
Siniscalchi, C., Perrella, A., Trama, U., Basaglia, M., Bernardi, F. F., & Micco, P. D. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1959476
Wang, M. K., Conen, D., Devereaux, P. J., Baskaran, G., Razeghi, G., Bell, C., Healey, J. S., Kamel, H., Lensing, A. W. A., McIntyre, W. F., et al. (2026) · Thrombosis Research · doi:10.1016/j.thromres.2026.109859
Self-citationA fresh look at extended-duration anticoagulation after venous thromboembolism
Sanches, S. M. V., Cerqueira, M. M. B. D. F., & Marques, M. A. (2026) · Jornal Vascular Brasileiro · doi:10.1590/1677-5449.202601062
Um novo olhar sobre a extensão da anticoagulação no tromboembolismo venoso
Sanches, S. M. V., Cerqueira, M. M. B. D. F., & Marques, M. A. (2026) · Jornal Vascular Brasileiro · doi:10.1590/1677-5449.202601061
(548493), R. L., Tao, Y., Dong, C., Chen, H., Shi, Y., Xu, X., Wang, M., Zhu, L., 施举红, Zhang, X., et al. (2026) · Thrombosis Research · doi:10.1016/j.thromres.2026.109892
Bai, H., Tang, Q., Jin, L., Yang, M., Fan, G., & Wu, S. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1855986
Craciun, M.-L., Avram, C. A., Pah, A.-M., Crișan, S., Mateescu, D.-M., Cotet, I.-G., Văcărescu, C., Pătru, O., & Rada, M. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.2002611
Patient Selection and Evidence for Intervention in Deep Vein Thrombosis and Pulmonary Embolism
Maćkowski, C., Krasiński, Z., Stanišić, M.-G., Kruszyna, Ł., & Salamaga, S. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15218212
Metadata
- Authors
- Weitz, J. I., Lensing, A. W. A., Prins, M. H., Bauersachs, R., Beyer-Westendorf, J., Bounameaux, H., Brighton, T. A., Cohen, A. T., Davidson, B. L., Decousus, H., Freitas, M. C. S., Holberg, G., Kakkar, A. K., Haskell, L., van Bellen, B., Pap, A. F., Berkowitz, S. D., Verhamme, P., Wells, P. S., & Prandoni, P.
- Affiliations
- University of Ottawa (CA)
- University of Geneva (CH)
- University of Padua (IT)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-03-30
- Volume
- 376
- Issue
- 13
- Pages
- 1211-1222
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2595086780
- Cited by
- 787
- References
- 32
- Citations by year
- 2026: 58 · 2025: 77 · 2024: 65 · 2023: 49 · 2022: 78 · 2021: 97 · 2020: 92 · 2019: 96 · 2018: 123 · 2017: 50
- FWCI
- 104.37
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (publishedVersion, other-oa)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- SERVAL (Université de Lausanne) (publishedVersion, other-oa)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion, other-oa)
- IRIS (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- UCL Discovery (University College London) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Funders
- Amgen
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- Sanofi
- Ionis Pharmaceuticals
- Janssen Scientific Affairs
- Novo Nordisk
- Novo Nordisk Fonden (NNF12OC1015957)
- LEO Pharma
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- venous thromboembolism, rivaroxaban, aspirin, long-term anticoagulation, recurrent venous thromboembolism, major bleeding, low-dose rivaroxaban, thromboprophylaxis, direct oral anticoagulants, adverse events, dose comparison, post-thrombotic syndrome
- MeSH terms
- Rivaroxaban, Adult, Aged, Aspirin, Double-Blind Method, Drug Administration Schedule, Female, Hemorrhage, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors, Kaplan-Meier Estimate, Venous Thromboembolism, Secondary Prevention, Intention to Treat Analysis, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.